Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Seven lung cancer drugs have been added to the interaction checker

Tuesday 05 April 2022

Afatinib, alectinib, amivantamab, gefitinib, necitumumab, osimertinib and pemetrexed are now listed in the interaction checker as cancer drugs and interactions can be found with all comedications.

  • Afatinib (Giotrif®, Gilotrif®) is an EGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
  • Alectinib (Alecensa®) is an ALK tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
  • Amivantamab (Rybrevant®) is a monoclonal antibody and is indicated for the treatment of non-small cell lung cancer.
  • Gefitinib (Iressa®) is an EGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
  • Necitumumab (Portazza®) is a monclonal antibody and is indicated for the treatment of non-small cell lung cancer.
  • Osimertinib (Tagrisso®) is an EGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
  • Pemetrexed (Alimta®, Pemfexy®, Ciambra®) is an antimetabolite and is indicated for the treatment of non-small cell lung cancer and mesothelioma.
ENDORSED BY
Bopa Esop gro%c3%9f %28resized%29